Neuropsychiatric effects of tenofovir in comparison with other antiretroviral drugs

Kathleen Ferrer¹,²
Natella Rakhmanina¹,²
¹Department of Pediatrics, George Washington University School of Medicine, Washington, DC, USA;
²Health Sciences Children’s National Medical Center, Washington, DC, USA

Abstract: Tenofovir is a widely used antiretroviral medication indicated to treat adults and children infected with HIV. Current guidelines for the management of HIV infection recommend tenofovir disoproxil fumarate (TDF) as a component of the preferred first-line combination antiretroviral therapy. The efficacy, tolerability, prolonged half-life allowing for once-daily administration, and availability as a component of several fixed-dose formulations make TDF an attractive choice for treatment-naive and treatment-experienced HIV-infected patients. TDF is also widely used as a component of postexposure prophylaxis in noninfected individuals. Most importantly, it has been recently approved for use as pre-exposure prophylaxis for non-infected adults and adolescents to reduce the risk of HIV transmission. With increasing use of TDF among adults and children, understanding of the potential for drug-associated side effects is important. This review focuses on the neuropsychiatric effects of tenofovir in adults and children with HIV infection in comparison with other antiretroviral drugs.

Keywords: HIV, tenofovir, neuropsychiatric effects

Introduction

Antiretroviral therapy (ART) has transformed the landscape of HIV medicine. Since the introduction of combination ART (cART) in the mid-nineties, the morbidity and mortality of patients with HIV infection has decreased dramatically.¹,² Combination of three or more antiretroviral (ARV) medications is required to achieve and maintain control of viral replication.¹ Currently, over 25 individual ARV medications are approved by the Food and Drug Administration (FDA) to treat HIV-infected patients in the United States. Knowledge about efficacy and toxicity of ARV drugs is crucial in designing the most potent, tolerable, and convenient ART to optimize outcome of HIV therapy.

Since its introduction, tenofovir (TFV) disoproxil fumarate (DF) has become an important component of cART in adolescents and adults. Tenofovir disoproxil fumarate (TDF) was approved by the US FDA for the treatment of HIV-1 infection in 2001 for adults and children older than 12 years of age. In January 2012, TDF was approved by the FDA for use in pediatric patients > 2 years of age and in July of 2012, the TDF coformulation with emtricitabine (FTC), Truvada (Gilead Sciences, Foster City, CA, USA), became the first drug approved by the FDA for use in noninfected adolescents and adults to reduce the risk of sexually acquired HIV infection as part of pre-exposure prophylaxis (PrEP).

Several clinical trials have demonstrated high efficacy of TDF in suppressing viral replication in both treatment-naive and treatment-experienced adult, adolescent, and...
pediatric patients. TDF has higher antiviral potency compared with other nucleoside reverse-transcriptase inhibitors (NRTIs) with the median decrease in plasma HIV RNA in subjects receiving TDF, zidovudine (AZT), or stavudine (d4T) monotherapy being 1.4, 0.5, and 0.5 log10, respectively. Pediatric studies have equally demonstrated excellent virologic response to TDF. Due to its efficacy, safety profile, and tolerability, TDF has been chosen as a component of preferred ART recommended as initial HIV treatment by the Department of Health and Human Services (DHHS) and the World Health Organization (WHO) guidelines for antiretroviral-naive adults and children (Table 1).

Additionally, in 2011 the HPTN 052 trial conducted by the HIV Prevention Trials Network in the US, showed that use of a TDF-containing regimen in an HIV-positive partner resulted in a 96% reduction in transmission risk. This study formed the basis for the concept of treatment as prevention, which has subsequently led to several studies investigating the safety and efficacy of using a TDF-containing regimen in noninfected individuals for PrEP.

With increasing use of TDF among adults and children, understanding of the potential for drug-associated side effects is important. This article will review the neuropsychiatric effects of TDF in comparison with other ARV drugs.

**Tenovir in clinical practice**

Classified as a nucleotide reverse-transcriptase inhibitor (NtRTI), TDF is a prodrug that is converted to TFV, an acyclic nucleoside phosphonate (nucleotide) analogue of adenosine 5'-monophosphate with activity against HIV-1, HIV-2, and hepatitis B. TDF prevents HIV replication by competitively inhibiting the enzyme reverse transcriptase and resulting in DNA chain termination in active and resting lymphoid cells and macrophages.

TDF is formulated as a tablet in strengths of 150, 200, 250, and 300 mg. Recently, a powder formulation has become available for oral administration in children. TDF has been coformulated with several other ARV medications. Truvada (Gilead Sciences) consists of TDF and another NRTI FTC. Atripla (Gilead Sciences and Bristol-Myers Squibb, New York, NY, USA) is a fixed-dose coformulation (FDC) of TDF with FTC and the first-generation non-nucleoside reverse-transcriptase inhibitor (NNRTI) efavirenz (EFV). The newest FDA-approved TDF containing coformulation is Complera (Gilead Sciences), which consists of TDF, FTC, and the second-generation NNRTI rilpivirine (RPV). All coformulations of TDF are especially attractive in clinical practice because they allow for once-daily administration of multiple drugs in a single pill, thus decreasing overall pill burden and creating a better setting for maintaining long-term adherence.

Due to low pill burden, availability in FDC, affordable cost, and storage, TDF is increasingly prescribed as a component of the ARV regimens used for the prevention of HIV transmission, including prevention of mother-to-child transmission and PrEP and postexposure prophylaxis (PEP) in noninfected adolescents and adults. In the Pediatric HIV/AIDS Cohort Study (PHACS), TDF use in HIV-infected women during pregnancy has been reported to have doubled in the last 5 years, with over 40% of pregnant mothers in the large study cohort receiving TDF. Recent studies (CARPRISA004, iPrEX, TDF2, Partners for PrEP) have investigated the use of TDF in noninfected adults for PrEP of HIV infection primarily through sexual contact. In the CARPRISA004 study, the use of 1% TFV gel by noninfected women with high risk for HIV exposure reduced risk of HIV acquisition by 39%. The studies of oral TDF/FTC (iPrEX and TDF2) reported 44% and 62% efficacy in preventing HIV transmission, respectively. The study Partners for PrEP demonstrated 63% reduction in HIV transmission in adults using mono-prophylaxis with oral TFV. Despite some contradicting results on low efficacy of oral TDF/FTC and TFV vaginal gel in two other studies (FEM-PrEP and VOICE), the evidence from studies demonstrating the efficacy of PrEP was considered sufficient by the FDA to approve the TDF-based FDC Truvada (Gilead Sciences) for use as PrEP in noninfected individuals in July 2012. With this new approval, the use of TDF in noninfected adolescents and adults is likely to increase significantly in the near future.

**Table 1 Summary of the DHHS and WHO adult and pediatric HIV treatment guideline recommendations**

<table>
<thead>
<tr>
<th>Year</th>
<th>DHHS US preferred regimens for antiretroviral-naive adult patients</th>
<th>WHO preferred regimens for antiretroviral-naive adult patients</th>
</tr>
</thead>
<tbody>
<tr>
<td>2012</td>
<td>Efavirenz/tenofovir/emtricitabine</td>
<td>Zidovudine + lamivudine + efavirenz</td>
</tr>
<tr>
<td></td>
<td>Ritonavir-boosted atazanavir + tenofovir/emtricitabine</td>
<td>Zidovudine + lamivudine + nevirapine</td>
</tr>
<tr>
<td></td>
<td>Ritonavir-boosted darunavir + tenofovir/emtricitabine</td>
<td>Tenofovir + (lamivudine or emtricitabine) + efavirenz</td>
</tr>
<tr>
<td></td>
<td>Raltegravir + tenofovir/emtricitabine</td>
<td>Tenofovir + (lamivudine or emtricitabine) + nevirapine</td>
</tr>
<tr>
<td>2010</td>
<td>2010 WHO preferred regimens for antiretroviral-naive adult patients</td>
<td>2011 DHHS preferred regimens for 2-NRTI backbone for antiretroviral-naive pediatric patients (for use with additional antiretroviral drugs)</td>
</tr>
<tr>
<td></td>
<td>Zidovudine + lamivudine + efavirenz</td>
<td>Abacavir + (lamivudine or emtricitabine) (children age ≥ 3 months)</td>
</tr>
<tr>
<td></td>
<td>Zidovudine + lamivudine + nevirapine</td>
<td>Tenofovir + (lamivudine or emtricitabine) (adolescents age ≥ 12 years and Tanner stage 4 or 5 only)</td>
</tr>
<tr>
<td></td>
<td>Tenofovir + (lamivudine or emtricitabine) + efavirenz</td>
<td>Zidovudine + (lamivudine or emtricitabine)</td>
</tr>
<tr>
<td></td>
<td>Tenofovir + (lamivudine or emtricitabine) + nevirapine</td>
<td>Abbreviations: DHHS, Department of Health and Human Services; WHO, World Health Organization; NRTI, nucleoside reverse-transcriptase inhibitor.</td>
</tr>
</tbody>
</table>
Pharmacokinetics and toxicity of TDF

TFV has a long half-life of approximately 17 hours, which allows for convenient once-daily dosing. TFV is water-soluble, and its oral bioavailability in fasted subjects is approximately 25%. High-fat meals increase bioavailability to 39% compared to light meals without significant effect. Unchanged TFV is excreted by the kidneys through a combination of glomerular filtration and active tubular secretion. Renal impairment (creatinine clearance < 50 mL/minute) requires reduction of TDF dosing with extended dosing intervals. Since TFV has minimal involvement with hepatic metabolism, no dose adjustment is required for patients with hepatic impairment or coinfection with hepatitis.

TFV is not involved with cytochrome (CYP) P450 metabolism, resulting in fewer drug–drug interactions than other ARV drugs, such as protease inhibitors (PIs). This lack of significant drug–drug interactions is particularly beneficial for HIV-infected patients who may have comorbidities requiring other medications. TDF, however, does have significant interaction with the NRTI didanosine (ddI). Coadministration of TDF and ddI results in increased ddI plasma concentrations and toxicity. DHHS guidelines recommend avoiding coadministration of these ARV drugs. If coadministration is required, ddI dose reduction is recommended with close monitoring for ddI-associated toxicity, such as pancreatitis and peripheral neuropathy.

Two important drug-related toxicities – renal and bone toxicity – have been associated with TDF use in children and adults. Rare cases of acute renal failure and Fanconi syndrome (dysfunction of renal tubules resulting in excessive renal loss of glucose, amino acids, and electrolytes) have been described in association with TDF exposure. The cumulative incidence of nephrotoxicity in TDF-containing regimens has been reported between 1% and 4%, with the rate of Fanconi syndrome between 0.5% to 2.0%. Nephrotoxicity most frequently occurs in patients with prior underlying renal abnormalities or those concomitantly exposed to other nephrotoxic agents. In clinical trials and practice, however, serious renal impairment associated with TDF has rarely been reported. The mechanism for renal toxicity is not well understood, but may involve adverse effects on transporter proteins in the kidney tubules. Following discontinuation of TDF, associated renal toxicity usually resolves without consequences. Current drug-manufacturer and treatment recommendations include assessing creatinine clearance prior to initiation and throughout the length of therapy with TDF, avoiding administration of TDF concurrently with other nephrotoxic drugs, and continued monitoring of renal function while on a TDF-containing regimen.

A decrease in bone mineral density (BMD) has also been observed in HIV-infected adult and pediatric patients treated with TDF-containing regimens, with dual X-ray absorptiometry demonstrating small decreases in spine and hip BMD. The reported decrease in BMD, however, does not appear to be clinically relevant in adult patients, except for the rare cases of osteomalacia reported with TDF use. Potential decreases in BMD are concerning for prepubertal children or adolescents in early stages of pubertal development. Studies have indicated that younger children (Tanner stages 1 and 2 of sexual maturation) may be at higher risk for TDF-associated decreases in BMD than older patients with more advanced stages of sexual development (Tanner stage ≥ 3).

Unlike other NRTIs, such as AZT and d4T, which have been linked to significant mitochondrial damage, TDF has been associated with minimal mitochondrial toxicity. Adverse effects, such as lipoatrophy, lactic acidosis, or peripheral neuropathy, are typically not related to TDF use. Nevertheless, rare cases of lactic acidosis and severe hepatomegaly with steatosis have been reported in patients treated with TDF, and discontinuation of TDF is recommended in any patient exhibiting clinical or laboratory findings suggestive of these side effects.

Neuropsychiatric complications of HIV and ART

Neuropsychiatric disease in HIV-infected patients may be caused by HIV infection itself, toxicity from ART, a preexisting underlying neuropsychiatric condition nonrelated to HIV, opportunistic comorbidities resulting from HIV-associated immunosuppression, or a combination of several of these conditions. Primary central nervous system (CNS) lymphoma and progressive multifocal leukoencephalopathy are associated with profound immune suppression. Additionally, opportunistic infections affecting the CNS, such as cryptococcosis and toxoplasmosis, may cause neurological manifestations in severely immunocompromised HIV-infected patients. Moreover, history of substance abuse, head injury, cerebral vascular accident, or aging can also contribute to the development of neuropsychiatric impairment in HIV-infected patients. Distinguishing the etiology of neuropsychiatric manifestations in HIV-infected patients in order to ensure the most optimal therapeutic approach is crucially important.

Neuropsychiatric effects of HIV

The direct effect of HIV infection on the CNS has been associated with the development of asymptomatic neurocognitive
impairment, HIV-associated neurocognitive disorder (HAND), and HIV-associated dementia (HAD), or AIDS dementia complex. HAD is the most severe neuropsychiatric manifestation of HIV. It is a clinical syndrome of severe cognitive, motor, and behavioral dysfunction that usually develops in patients with untreated HIV infection.\(^{42}\) HAND is considered to be less severe than HAD, with symptoms including impaired memory, attention, processing speed, and executive functioning; speech, language, visuospatial deficits; and slowing of psychomotor processing and motor speed.\(^{43}\)

HIV penetrates the CNS soon after infection via infected immune cells, such as CD4\(^+\) T lymphocytes, dendritic cells, monocytes, and macrophages. As a major target of HIV, the CNS continues to be affected by the virus throughout the course of the disease.\(^{44}\) Subtype-D HIV has been implicated in being more neurovirulent than other subtypes in adults.\(^{45}\)

Cognitive impairment frequently develops secondary to chronic inflammation, resulting in neurodegeneration.\(^{46}\) The level of HIV viremia (HIV RNA) in cerebrospinal fluid (CSF) has been shown to correlate with severity of HIV-associated dementia and neuropsychological test performance. Elevated HIV RNA in CSF can predict the development of subsequent neurocognitive impairments.\(^{47-51}\) Following the introduction and effective application of ART in clinical settings, a profound reduction in the incidence and severity of HAD, as well as major CNS opportunistic infections, has been observed.\(^{43}\) The dramatic decrease in incidence of HAD from >50% to 2%–8% has been suggested to be mediated by suppression of HIV replication and reduction in circulating lipopolysaccharide, both preventing compromise of the blood–brain barrier and migration of HIV-infected monocytes from systemic circulation into the brain.\(^{52,53}\) A multicenter study of HIV-infected older children (7–16 years of age) in the US and Puerto Rico demonstrated that neurocognitive deficits acquired in early childhood were reversible with consistent use of ART in pediatric patients with HIV infection.\(^{54}\) As a component of cART therapy, TFV has contributed to the decrease in severe neuropsychiatric manifestations of HIV disease.

Although clear evidence supports the success of cART in prevention of the severe neuropsychiatric disease associated with HIV, the prevalence of minor HIV-associated cognitive impairment appears not to be affected by cART and has been noted to be on the rise in recent years.\(^{55,56}\) This effect can be partially due to improved survival and longevity of the patients with HIV infection with modern, highly effective cART. Cohort studies have described a prevalence of demonstrable cognitive impairments in 30%–60% of HIV-infected adults.\(^{44}\) Not surprisingly, the history of low nadir in CD4\(^+\) cell count below 50 cells/mm\(^3\) was linked to a greater risk of neurocognitive impairment.\(^{56}\) Similar to adults, children with history of severe immunosuppression were also more likely to have residual neurocognitive deficits.\(^{56}\) The constant presence of low levels of HIV in the CNS along with the associated immune activation and ongoing inflammation may be related to more subtle forms of brain injury, which has become a focus of clinical attention and research in the cART era.\(^{44}\)

HAND and neurocognitive impairment continue to be diagnosed even among HIV-infected patients with immune recovery on cART.\(^{53,57,58}\) The presence of HAND in patients effectively treated with ARVs may be caused by limited penetration and distribution of ARV drugs in the CNS.\(^{46}\) The normal function of the blood–brain and blood–CSF barriers is to shield the brain from harmful, toxic substances and provide a precisely regulated environment in the CNS. The CNS acts as a sanctuary site for HIV, and HIV replication can persist despite virologic suppression in blood and other tissues.\(^{59}\) This ongoing low-level viral replication within the CNS may lead to neuronal damage, resulting in long-term cognitive impairment.

Minor HIV-associated cognitive impairment may also be caused by the insurgence of drug-resistant HIV in the CNS while on cART.\(^{60}\) By limiting CNS penetration of ARV drugs, the blood–brain/blood–CSF barrier potentially decreases CNS toxicity of ARV medications, but also contributes to continued presence of HIV in the CNS despite an undetectable HIV RNA viral load in the peripheral blood stream. Hindering the penetration of ARV drugs into the CNS can therefore result in subtherapeutic ARV drug concentrations, resulting in the development of drug resistance and ongoing replication of the HIV within CNS. Ultimately, this may contribute to treatment failure and persistent neurocognitive deficits, even in the presence of effective cART.\(^{46}\)

**Neuropsychiatric effects of ART**

Continued presence of minor cognitive impairment in HIV-infected patients on ART may be caused by the toxicity of ARV drugs, especially those with higher CNS penetration. ART-related CNS toxicity may be due to direct ARV drug CNS toxicity and/or CNS immunopathology related to immune restoration in the presence of ART.\(^{60}\) Efforts have been made to classify ARV drugs according to their ability to penetrate the CNS. In 2008, Letendre et al devised and validated a method to quantify the penetration of ARVs into
the CNS by giving each ARV drug a CNS penetration effectiveness (CPE) score. Currently available information about ARV drug characteristics, measured CSF concentrations, and effectiveness in the CNS were used to rank ARV drugs relative to one another with regard to their ability to penetrate the CNS. The authors revised the CPE ranking in 2010 to include ARVs from newer classes of drugs (Table 2). ARV regimens with estimated good CNS penetration are generally more effective than regimens with worse CNS penetration in controlling CSF viral replication, and may contribute to the more significant restoration and preservation of neurocognitive function. Smurzynski et al found that in patients using ART regimens containing more than three ARV drugs, the use of high versus low CPE scoring regimens was correlated with better scores on neurocognitive testing. This relationship, however, was not reported in patients using ART with three or less ARV drugs.

Better CNS-penetrating ART provides better control of viral replication within the CNS; however, HIV suppression below the levels of detection does not guarantee full cognitive recovery. Interestingly, a study by Marra et al suggested that ARV drugs with good CNS penetration were associated with worse neurocognitive performance. In this study, ART regimens with CPE ≥ 2, indicating good CNS penetration, were compared to regimens with CPE < 2. The use of a regimen with CPE ≥ 2 was significantly associated

Table 2 CPE scores and selected common CNS adverse events associated with ARV medications (as cited in DHHS guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents and guidelines for the use of antiretroviral agents in pediatric HIV infection)

<table>
<thead>
<tr>
<th>ARV drug</th>
<th>CPE score</th>
<th>Headache</th>
<th>Dizziness</th>
<th>Asthenia</th>
<th>Insomnia</th>
<th>Depression</th>
<th>Other CNS^</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Nucleoside (nucleotide) reverse-transcriptase inhibitors</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Zidovudine</td>
<td>4</td>
<td>x</td>
<td></td>
<td></td>
<td>x</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Abacavir</td>
<td>3</td>
<td>x</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Didanosine</td>
<td>2</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Emtricitabine</td>
<td>3</td>
<td>x</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Lamivudine</td>
<td>2</td>
<td>x</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Stavudine</td>
<td>2</td>
<td>x</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tenofovir</td>
<td>1</td>
<td>x</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Nonnucleoside reverse-transcriptase inhibitors</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Efavirenz</td>
<td>3</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td>x</td>
</tr>
<tr>
<td>Etravirine</td>
<td>2</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Nevirapine</td>
<td>4</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Rilpivirine</td>
<td>2</td>
<td>x</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>x</td>
</tr>
<tr>
<td><strong>Protease inhibitors</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Atazanavir</td>
<td>x</td>
<td>x</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Atazanavir/ritonavir</td>
<td>2</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Darunavir</td>
<td>x</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Darunavir/ritonavir</td>
<td>3</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Fosamprenavir</td>
<td>2</td>
<td>x</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Fosamprenavir/ritonavir</td>
<td>3</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Indinavir</td>
<td>3</td>
<td>x</td>
<td>x</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Indinavir/ritonavir</td>
<td>4</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Lopinavir/ritonavir</td>
<td>3</td>
<td>x</td>
<td>x</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Nelfinavir</td>
<td>1</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ritonavir</td>
<td>1</td>
<td>x</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tipranavir</td>
<td>x</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tipranavir/ritonavir</td>
<td>1</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Saquinavir</td>
<td>1</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Saquinavir/ritonavir</td>
<td>1</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Entry inhibitors</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Enfuvirtide</td>
<td>1</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Maraviroc</td>
<td>3</td>
<td></td>
<td>x</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Integrase inhibitor</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Raltegravir</td>
<td>3</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Notes: ^Other CNS symptoms include somnolence, abnormal dreams, impaired concentration, agitation, psychosis, abnormal thinking, hallucinations, euphoria, seizures; ^rare cases of intracranial hemorrhage reported in adults; ^global CNS depression reported in premature infants. into the CNS (4 = highest penetration, 3 = high, 2 = intermediate, 1 = low); ^larger numbers reflect estimates of better penetration. 

Abbreviations: ARV, antiretroviral; CNS, central nervous system; CPE, CNS penetration effectiveness.
with worse Z-scores on a short-battery neuropsychological test despite better control of CSF viral replication with ARV regimens with good CSF penetration. The authors concluded that ARV regimens with better CSF penetration may not lead to improved neurocognitive performance. It is important to recognize that the interpretation of study results was limited due to the small number of subjects, with only 75 subjects participating in the short-battery neuropsychological testing. Another study of HIV-infected adults compared the overall neurological and neuropsychological effects of ARV regimens. In this study, by Robertson et al, subjects were randomized to three treatment arms: A (lamivudine [3TC], AZT, plus EFV), B (FTC, ddI, plus atazanavir [ATV]) and C (FTC, TDF, plus EFV). Standardized neurological and neuropsychological examinations were administered every 24 weeks during the study period of 4 years. Each study arm was assigned a CPE score according to Letendre’s ranking system. The total CPE score for arms A, B, and C, were 9, 7, and 7, respectively, with a higher score indicating higher CNS penetration of the overall ART regimen. The study detected no significant differences in neurological and neuropsychological outcomes between the randomized ART combinations. Authors concluded that regimens with higher CPE scores did not correlate with additional neurological or neuropsychological benefit. Overall, however, significant improvement in neurological and neuropsychological outcomes did occur over time after initiation of ART, regardless of ARV drug combination.

Although overall rates of treatment-limiting CNS adverse events of ART are low, especially with newer ARV drugs, cognizance of such events is important, since they can directly affect adherence to ART. Drug-induced CNS adverse reactions attributable to individual ARV drugs can result in a spectrum of symptoms, ranging from sleep disturbance to cognitive impairment and psychosis. Complex drug interactions between ARV drugs could also contribute to CNS toxicity. Published case reports and clinical studies of ARV-associated CNS toxicity most commonly report causative relationships between neuropsychiatric complications of ART and NRTIs (AZT and abacavir [ABC]), NNRTIs (EFV and RPV) and several PIs. While neuropsychiatric side effects may occur with almost all ARV medications, the majority of them are self-limited and do not result in discontinuation of medication. In a study that reviewed reasons for discontinuation of ART, adverse events accounted for 24% (n = 84) of reasons for discontinuing therapy. Of all adverse events (n = 84), CNS complaints were cited in significantly smaller proportion (10%; n = 8), compared to the gastrointestinal abnormalities observed in 44% (n = 37) of patients. Among the CNS complaints, headache, insomnia, and dizziness were responsible for 7%, 7%, and 5% of all adverse events, respectively.

Headache is the most frequently cited adverse event for NRTIs such as AZT, abacavir, FTC, 3TC, d4T, and TDF for children and adults. Typically, the headache is transient, mild to moderate in severity, and can be treated symptomatically. AZT has also been associated with the side effects of insomnia and asthenia.

Headache has also been implicated as a common drug toxicity for certain PIs, including ATV, darunavir, fosamprenavir, indinavir (IDV), lopinavir/ritonavir (LPV/RTV) and tipranavir. Additionally, IDV, LPV/RTV, and RTV have been associated with asthenia, while ATV and IDV have also been associated with dizziness. As with NRTIs, these side effects are often self-limited and only mild to moderate in severity, usually not requiring a switch in ART. Notably, tipranavir has been linked with rare cases of intracranial hemorrhage and should be used cautiously in patients with prior history of intracranial lesions or bleeding disorder. The propylene glycol and alcohol components of the LPV/RTV oral solution may also contribute to global CNS depression reported in neonates and preterm infants and limits the use of this combination PI in premature and young infants to those with postmenstrual age of >42 weeks and a postnatal age of >14 days. LPV/RTV-associated CNS depression typically resolves within 1–5 days of discontinuation of the drug.

Neuropsychiatric side effects of the newer classes of ARV medications, such as the entry inhibitor maraviroc, include dizziness and postural hypotension, while the integrase inhibitor raltegravir has been associated with headaches and dizziness. Table 2 summarizes selected common CNS adverse events for ARV drugs as cited by DHHS adult and pediatric guidelines for use of ARV agents.

A high incidence of the neuropsychiatric effects, ranging from 40% to 70%, has been reported in association with NNRTI EFV. EFV crosses the blood–brain barrier well, and CSF-to-plasma ratios have been found to range between 0.65% and 1.19%. Neuropsychiatric manifestations most commonly associated with EFV use include dizziness, confusion, lethargy, impaired concentration, amnesia, hallucinations, abnormal dreams, insomnia, sleep disorders, depression, and irritability. The CNS symptoms usually appear in the first weeks of therapy and abate within several weeks. While the exact mechanism responsible for these neuropsychiatric effects by EFV has not been established, some studies suggest that the CNS side effects are related to...
the higher level of plasma EFV exposure > 4000 ng/mL. Since EFV is the substrate to the CYP450 2B6 metabolic pathway, the polymorphisms in CYP2B6 (particularly 516 T > G) has been reported to increase the EFV plasma exposure and the severity of EFV-associated neurotoxicity.

A second-generation NNRTI RPV has also been associated with CNS adverse events, including depression, insomnia, and headache. From safety and efficacy studies comparing RPV and EFV, of 686 subjects on RPV, the most common treatment-related adverse events (≥grade 2) included dizziness (1%, n = 7), abnormal dreams/nightmares (1%, n = 4), headache (2%, n = 9), and insomnia (2%, n = 12). When considering all grades of RPV-related adverse events, any form of neurologic adverse event was reported in 17% (n = 117) of the subjects, with 8% (n = 55) complaining of dizziness, while any form of psychiatric adverse event was reported in 15% (n = 102) of subjects, with 8% (n = 56) complaining of abnormal dreams/nightmares. The frequency of dizziness and abnormal dreams/nightmares for RPV was significantly lower than that reported in association with EFV, whereas the incidence of depression was similarly low for both groups.

Neuropsychiatric effects of TDF

TFV belongs to the class of ARV drugs with low penetration into the CNS. Animal data indicate that TFV is transported across the blood–CSF barrier but not the blood–brain barrier, due to physicochemical properties of the drug. Its high polarity and low lipid solubility reduce its ability to readily undergo passive diffusion to cross the blood–brain barrier. The penetration of TFV into the brain, therefore, relies on active transport systems to cross the blood–brain/blood–CSF barrier. These transporters are responsible for both efflux and influx of TFV into the CNS. Concentrations of TFV in the CSF have been found to be only 5% of plasma concentrations.

With limited penetration into the CNS, TFV is unlikely to produce direct adverse effects on the CNS. During phase II and III clinical trials, TDF exhibited limited neuropsychiatric effects. In the Gilead Sciences study GS-99-903, a double-blind comparative controlled trial designed to evaluate the safety of TDF in adults, the most common neuropsychiatric adverse reactions attributable to the study drug were headache and dizziness. Overall, from three large controlled clinical trials, the most common TDF-associated neuropsychiatric adverse reactions with incidence ≥ 10% and grades 2–4 included headache, depression, and asthenia. In an equivalency trial designed to assess efficacy and safety of TDF, cART consisting of TDF, 3TC, and EFV was compared to a regimen containing d4T, 3TC, and EFV. Overall frequency of grade 2–4 neuropsychiatric adverse events including asthenia (6%–7%), depression (10%–11%), and anxiety (6%) were similar between the two groups throughout 144 weeks of follow-up. A smaller proportion of patients using the TDF/3TC/EFV regimen reported headache (14% versus 17%), insomnia (5% versus 8%), dizziness (3% versus 6%), and peripheral neuropathy (1% versus 5%) compared to those taking d4T/3TC/EFV.

In an open-label noninferiority study comparing two ARV regimens TDF/FTC/EFV with AZT/3TC/EFV, patients receiving a TDF-containing ART reported similar frequency of neuropsychiatric adverse events in grades 2–4, such as headache (5%–6%), dizziness (7%–8%), insomnia (5%–7%), and depression (7%–9%) as those on a regimen without TDF.

A case series described nine episodes of neuropsychiatric intolerance occurring early after a switch from an ART regimen without TDF to a TDF-containing regimen. Moderate to severe neuropsychiatric adverse events were noted almost immediately after TDF initiation. CNS symptoms included nightmare (n = 4), insomnia (n = 3), dizziness (n = 4), tinnitus (n = 1), nausea (n = 1), and irritability (n = 1). CNS symptoms occurring during the 24 months after initiation of TDF included nightmares (n = 4) and insomnia (n = 2). Due to these side effects, five out of the nine patients switched ARV regimen (discontinuing TDF), and one discontinued ARV therapy altogether. CNS symptoms improved in all six who changed or discontinued regimens. In the three patients who did not switch regimens, one had spontaneous resolution of symptoms within 2 weeks, and two continued to experience sleeping disorders.

The mechanism of the emerging CNS adverse effects after the introduction of TDF to an EFV-containing regimen remains unclear. It was hypothesized that the neuropsychiatric effects may have been the result of an unexplained interaction between EFV and TDF that resulted in increased levels of EFV, likely causing the neuropsychiatric side effects. The possibility of PK interaction between TDF and EFV has been questioned, especially among patients with polymorphism of CYP2B6 who are slow EFV metabolizers. The study, evaluating EFV and TDF exposure, reported similar EFV area under the plasma vs time curve concentrations (AUC) among the adult patients, except for the significantly higher exposure among patients with CYP2B6 polymorphism and patients receiving concomitant TFV (n = 5; AUC=353,031 ng*h/mL) compared to those not receiving TFV (n = 18; AUC=180,689 ng*h/mL). Typically, however, the concomitant administration of TDF and EFV has not been associated with significant PK/pharmacodynamic interactions.
Conclusion

As the armamentarium of ARV drugs continues to grow, understanding the potential benefits and risks of each ARV agent is essential in designing the most optimal regimen for individual patients. TDF, coformulated in multiple FDCs, is widely recommended for treatment and prophylaxis of HIV infection due to its potency, safety, tolerability, and convenient dosing. The potency of TDF has been instrumental in successfully suppressing viral replication and decreasing incidence of severe neuropsychiatric disorders associated with advanced HIV infection. The low CNS penetration by TFV is likely responsible for the minimal spectrum of neuropsychiatric adverse effects associated with the drug. The same low CNS penetration of TDF, however, may limit its ability to independently reduce HIV viral load in the CNS, potentially contributing to persistent low-level HIV viremia, leading to mild neuropsychiatric impairments and/or development of drug resistance. Combining TDF with ARV drugs with high CNS penetration may be strategically beneficial for the long-term management of HIV-infected patients. In patients on TDF-containing regimens, early recognition of neuropsychiatric disorders is essential to achieve a high quality of life and most beneficial long-term outcome of HIV infection.

More clinical studies evaluating the long-term neuropsychological, neurocognitive, and neurodevelopmental effects of ARV regimens, particularly among HIV-infected children and elderly patients, are needed. Specifically, future studies should evaluate the relationship between particular ARV regimen DNA-PK scores, CSF viral replication, and overall neurological outcome to allow clinicians to estimate the benefits and risks of high CNS penetrating ART. Eventually, this research could provide valuable insight for improving the selection of ART to ensure most optimal long-term neurological outcomes for HIV-infected patients.

Acknowledgment

N Rakhmanina is supported by Department of Health and Human Services, NIH PHS grant NICHD K23 HD060452.

Disclosure

The authors have no conflicts of interest to declare.

References


